Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas

European Journal of Cancer Part A

Volumn 33, Issue 4, 1997, Pages 691-693

  Volm, M ^a   Koomagi R ^a   Mattern, J ^a   Stammler, G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

basic fibroblast growth factor; FGFR 1; immunohistochemistry; lung carcinomas; survival

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR UPREGULATION;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 0343471392     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00411-X     Document Type: Article

References (11)

1. Baird A, Klagsbrun M. The fibroblast growth factor family. Ann NY Acad Sci 1991, 638, 403-477.
2. Nanus DM, Schmitz-Dräger BJ, Motzer RJ, et al. Expression of basic fibroblast human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993, 85, 1597-1599.
3. Ohta T, Yamamoto M, Numata M, et al. Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer 1995, 72, 824-831.
4. Carr DT, Mountain CF. Staging lung cancer. In Straus MJ, ed. Lung Cancer: Chemical Diagnosis and Treatment. New York, Grune and Stratton, 1977, 151-161.
5. World Health Organization. Histological typing of lung tumours. Tumori 1981, 6, 253-272.
6. Volm M, Bak M, Efferth T, Lathan B, Mattern J. Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4. Anticancer Res 1988, 8, 531-536.
7. Volm M, Mattern J, Samsel B. Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein, and glutathione S-transferase-π in human lung tumors. Cancer 1993, 71, 3181-3187.
8. Volm M, Mattern J, Stammler G, et al. Expression of resistance-related proteins in nephroblastoma after chemotherapy. Int J Cancer 1995, 63, 193-197.
9. Moscatelly D, Joseph-Silverstin J, Manejias R, Ritkin DB. Mr 25.000 heparin-binding protein from guinea pig brain is a high molecular weight form of basic fibroblast growth factor. Proc Natl Acad Sci 1987, 84, 5778-5782.
10. Mohammadi M, Honegger AM, Rotin D, et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-γ1. Mol Cell Biol 1991, 11, 5068-5078.
11. Byar DP. Analysis of survial data: Cox and Weibull models with covariates. In Mike V, Stanley KE, eds. Statistics in Medical Research. Methods and Issues with Application in Cancer Research. John Wiley, New York, 1982, 365-401.